These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28377179)

  • 1. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
    Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
    Sokolenko AP; Bizin IV; Preobrazhenskaya EV; Gorodnova TV; Ivantsov AO; Iyevleva AG; Savonevich EL; Kotiv KB; Kuligina ES; Imyanitov EN
    Int J Cancer; 2020 Apr; 146(7):1879-1888. PubMed ID: 31693165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation.
    Sokolenko A; Preobrazhenskaya E; Marchetti C; Piermattei A; Zagrebin F; Kuligina E; Gorodnova T; Pavone M; Ivantsov A; Bizin I; Scambia G; Berlev I; Fagotti A; Imyanitov E
    Pathobiology; 2024; 91(2):108-113. PubMed ID: 37579727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Gorodnova TV; Sokolenko AP; Ivantsov AO; Iyevleva AG; Suspitsin EN; Aleksakhina SN; Yanus GA; Togo AV; Maximov SY; Imyanitov EN
    Cancer Lett; 2015 Dec; 369(2):363-7. PubMed ID: 26342406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
    Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor
    Afghahi A; Timms KM; Vinayak S; Jensen KC; Kurian AW; Carlson RW; Chang PJ; Schackmann E; Hartman AR; Ford JM; Telli ML
    Clin Cancer Res; 2017 Jul; 23(13):3365-3370. PubMed ID: 28087643
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
    Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
    Gorodnova TV; Maksimov SIa; Guseĭnov KD; Imianitov EN
    Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
    Gorodnova TV; Kotiv KB; Ivantsov AO; Mikheyeva ON; Mikhailiuk GI; Lisyanskaya AS; Mikaya NA; Guseynov KD; Bondarev NE; Matveyeva NS; Nekrasova EA; Sidoruk AA; Roman LD; Manikhas GM; Belyaev AM; Sokolenko AP; Berlev IV; Imyanitov EN
    Int J Gynecol Cancer; 2018 Oct; 28(8):1498-1506. PubMed ID: 30247247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor α-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Wang J; Gao H; Liu G; Gu L; Yang C; Zhang F; Liu T
    Hum Pathol; 2018 Dec; 82():239-248. PubMed ID: 30107189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of bevacizumab to neoadjuvant chemotherapy for Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report.
    Liu H; Shi Y; Zhang GN; Song SQ; Hu T
    Eur J Gynaecol Oncol; 2015; 36(3):341-5. PubMed ID: 26189267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
    J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
    Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD
    J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in
    Sokolenko AP; Moiseyenko FV; Iyevleva AG; Ivantsov AO; Dolmatov GD; Shelekhova KV; Gulo EV; Topal AX; Artemieva EV; Abduloeva NH; Rysev NA; Barsova DA; Levchenko NV; Volkov NM; Egorenkov VV; Moiseyenko VM; Imyanitov EN
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.